141 related articles for article (PubMed ID: 21531726)
21. Transcriptional repression of taurine transporter gene (TauT) by p53 in renal cells.
Han X; Patters AB; Chesney RW
J Biol Chem; 2002 Oct; 277(42):39266-73. PubMed ID: 12163498
[TBL] [Abstract][Full Text] [Related]
22. Tumor suppressor RASSF1A promoter: p53 binding and methylation.
Tian Y; Hou Y; Zhou X; Cheng H; Zhou R
PLoS One; 2011 Feb; 6(2):e17017. PubMed ID: 21364923
[TBL] [Abstract][Full Text] [Related]
23. p53 inhibition of AP1-dependent TFF2 expression induces apoptosis and inhibits cell migration in gastric cancer cells.
Tu SP; Chi AL; Ai W; Takaishi S; Dubeykovskaya Z; Quante M; Fox JG; Wang TC
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G385-96. PubMed ID: 19541923
[TBL] [Abstract][Full Text] [Related]
24. Analysis of regulator of G-protein signaling-2 (RGS-2) expression and function in osteoblastic cells.
Thirunavukkarasu K; Halladay DL; Miles RR; Geringer CD; Onyia JE
J Cell Biochem; 2002; 85(4):837-50. PubMed ID: 11968023
[TBL] [Abstract][Full Text] [Related]
25. pRb, Myc and p53 are critically involved in SV40 large T antigen repression of PDGF beta-receptor transcription.
Uramoto H; Hackzell A; Wetterskog D; Ballági A; Izumi H; Funa K
J Cell Sci; 2004 Aug; 117(Pt 17):3855-65. PubMed ID: 15265983
[TBL] [Abstract][Full Text] [Related]
26. The activity of the murine Bax promoter is regulated by Sp1/3 and E-box binding proteins but not by p53.
Schmidt T; Körner K; Karsunky H; Korsmeyer S; Müller R; Möröy T
Cell Death Differ; 1999 Sep; 6(9):873-82. PubMed ID: 10510469
[TBL] [Abstract][Full Text] [Related]
27. Positive and negative regulation of deltaN-p63 promoter activity by p53 and deltaN-p63-alpha contributes to differential regulation of p53 target genes.
Harmes DC; Bresnick E; Lubin EA; Watson JK; Heim KE; Curtin JC; Suskind AM; Lamb J; DiRenzo J
Oncogene; 2003 Oct; 22(48):7607-16. PubMed ID: 14576823
[TBL] [Abstract][Full Text] [Related]
28. Human papillomavirus oncogenic E6 protein regulates human β-defensin 3 (hBD3) expression via the tumor suppressor protein p53.
DasGupta T; Nweze EI; Yue H; Wang L; Jin J; Ghosh SK; Kawsar HI; Zender C; Androphy EJ; Weinberg A; McCormick TS; Jin G
Oncotarget; 2016 May; 7(19):27430-44. PubMed ID: 27034006
[TBL] [Abstract][Full Text] [Related]
29. Identification and characterization of the IKKalpha promoter: positive and negative regulation by ETS-1 and p53, respectively.
Gu L; Zhu N; Findley HW; Woods WG; Zhou M
J Biol Chem; 2004 Dec; 279(50):52141-9. PubMed ID: 15469934
[TBL] [Abstract][Full Text] [Related]
30. MDM2 induces NF-kappaB/p65 expression transcriptionally through Sp1-binding sites: a novel, p53-independent role of MDM2 in doxorubicin resistance in acute lymphoblastic leukemia.
Gu L; Findley HW; Zhou M
Blood; 2002 May; 99(9):3367-75. PubMed ID: 11964305
[TBL] [Abstract][Full Text] [Related]
31. YY1 and NF1 both activate the human p53 promoter by alternatively binding to a composite element, and YY1 and E1A cooperate to amplify p53 promoter activity.
Furlong EE; Rein T; Martin F
Mol Cell Biol; 1996 Oct; 16(10):5933-45. PubMed ID: 8816507
[TBL] [Abstract][Full Text] [Related]
32. DNA damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: one involves direct binding to the cdc25C promoter.
St Clair S; Giono L; Varmeh-Ziaie S; Resnick-Silverman L; Liu WJ; Padi A; Dastidar J; DaCosta A; Mattia M; Manfredi JJ
Mol Cell; 2004 Dec; 16(5):725-36. PubMed ID: 15574328
[TBL] [Abstract][Full Text] [Related]
33. SAK, a new polo-like kinase, is transcriptionally repressed by p53 and induces apoptosis upon RNAi silencing.
Li J; Tan M; Li L; Pamarthy D; Lawrence TS; Sun Y
Neoplasia; 2005 Apr; 7(4):312-23. PubMed ID: 15967108
[TBL] [Abstract][Full Text] [Related]
34. ECRG2, a novel transcriptional target of p53, modulates cancer cell sensitivity to DNA damage.
Patel H; Sheikh MS; Huang Y
Cell Death Dis; 2020 Jul; 11(7):543. PubMed ID: 32681017
[TBL] [Abstract][Full Text] [Related]
35. E2F1 inhibits MDM2 expression in a p53-dependent manner.
Tian X; Chen Y; Hu W; Wu M
Cell Signal; 2011 Jan; 23(1):193-200. PubMed ID: 20837136
[TBL] [Abstract][Full Text] [Related]
36. CITED2 silencing sensitizes cancer cells to cisplatin by inhibiting p53 trans-activation and chromatin relaxation on the ERCC1 DNA repair gene.
Liu YC; Chang PY; Chao CC
Nucleic Acids Res; 2015 Dec; 43(22):10760-81. PubMed ID: 26384430
[TBL] [Abstract][Full Text] [Related]
37. p53-dependent repression of the human MCL-1 gene encoding an anti-apoptotic member of the BCL-2 family: the role of Sp1 and of basic transcription factor binding sites in the MCL-1 promoter.
Pietrzak M; Puzianowska-Kuznicka M
Biol Chem; 2008 Apr; 389(4):383-93. PubMed ID: 18208354
[TBL] [Abstract][Full Text] [Related]
38. Identification of PRC1 as the p53 target gene uncovers a novel function of p53 in the regulation of cytokinesis.
Li C; Lin M; Liu J
Oncogene; 2004 Dec; 23(58):9336-47. PubMed ID: 15531928
[TBL] [Abstract][Full Text] [Related]
39. The proapoptotic gene SIVA is a direct transcriptional target for the tumor suppressors p53 and E2F1.
Fortin A; MacLaurin JG; Arbour N; Cregan SP; Kushwaha N; Callaghan SM; Park DS; Albert PR; Slack RS
J Biol Chem; 2004 Jul; 279(27):28706-14. PubMed ID: 15105421
[TBL] [Abstract][Full Text] [Related]
40. Toll-like receptor signaling alters the expression of regulator of G protein signaling proteins in dendritic cells: implications for G protein-coupled receptor signaling.
Shi GX; Harrison K; Han SB; Moratz C; Kehrl JH
J Immunol; 2004 May; 172(9):5175-84. PubMed ID: 15100254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
